Helixmith

Focus: Helixmith is a Korean biotech company specializing in plasmid DNA-based gene therapy, focused on neurological, vascular, and inflammatory diseases.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Helixmith

AI assessmentNot Hiring

No open roles listed right now. Follow Helixmith to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

5 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VM202 2 mg

Critical Limb Ischemia

Phase 1

Clinical Trials (1)

NCT00696124Safety Study of Gene Therapy in Treating Critical Leg Ischemia

Phase 1

Help build intelligence for Helixmith

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading position in plasmid DNA gene therapy, an emerging modality with significant IP and differentiation potential
Robust pipeline with 20 active programs across Phase 1-3, including Phase 3 Engensis program for multiple diabetic neuropathy indications
Exposure to high-value therapeutic areas including ALS, critical limb ischemia, and diabetic complications with large patient populations

Watch Out For

No current open positions listed, suggesting limited near-term hiring or potential organizational consolidation
Lacks disclosed financial data (revenue, R&D spend, cash position), making it difficult to assess long-term runway and stability

Generated by Claude from Helixmith's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

VM202

Painful Diabetic Peripheral Neuropathy

Phase 1/2

Clinical Trials (1)

NCT01002235Gene Therapy for Painful Diabetic Neuropathy

Phase 1/2

VM202-0.5 mg

Ischemic Heart Disease

Phase 1/2

Clinical Trials (1)

NCT01422772Safety Study of Gene Therapy for Ischemic Heart Disease in Korea

Phase 1/2